Gapping down
News:
- ACRS -36.5% (preliminary topline data from 12-week phase 2a study of oral zunsemetinib; study did not meet primary or secondary efficacy endpoints)
- ESPR -26.2% (reports Landmark CLEAR outcomes study demonstrates NEXLETOL tablet is the only LDL-C lowering therapy since statins to reduce hard ischemic events)
- ADAP -25.6% (Adaptimmune Therapeutics and TCR² Therapeutics (TCRR) announce strategic combination)
- DV -3.8% (launches offering of 12.5 mln shares of common stock by Providence VII U.S. Holdings L.P. and Providence Butternut Co-Investment L.P.)
- INCY -2.7% (to discontinue Phase 3 LIMBER-304 trial following results of a pre-planned interim analysis)
- RNG -2.2% (files for 1,265,456 share common stock offering by selling shareholders)
- PGTI -1.9% (CFO John Kunz has stepped down, effective Feb 27)
- AL -1.9% (announced long-term lease placements for three new Airbus A350-900 widebody aircraft with Air France)
- AVB -1.5% (reports February operating metrics)
- NSC -1.5% (Second NSC train derails in Ohio about a month after East Palestine derailment; no hazardous materials were involved, according to NYT)
- CBOE -1.1% (Reports Trading Volume for February)
Analyst comments:
- SI -8.7% (downgraded to Underperform from Neutral at Wedbush)
- BIRD -2.3% (downgraded to Neutral from Outperform at Wedbush)
- KBH -1.4% (downgraded to Underweight from Overweight at JP Morgan)
- WEN -1.4% (downgraded to Neutral from Buy at Northcoast)